DonateRead the latest news about Make 2nds Count and secondary breast cancer.
For comms and press enquiries, please contact our Communications and Marketing Manager: clare.cox@make2ndscount.co.uk
Keep up-to-date with the latest news by signing up to our news bulletin and by following us on Twitter and Instagram.
12th March 2024
Medicine for rare form of breast cancer approved for use on the NHS in Scotland
Make 2nds Count is pleased to hear from the Scottish Medicines Consortium (SMC) that Talazoparib (Talzenna) has been approved to treat adults with BRCA1 or 2 mutated HER2-negative secondary breast cancer. The announcement is welcome news for many people in Scotland and their families as this is the first ever BRCA-targeted treatment for those living with locally advanced or secondary breast cancer.